Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 2
---
 PLAN OF DISTRIBUTION                                                                               | 130 |
| ​                                                                                                  |   ​ |
| EXPERTS                                                                                            | 132 |
| ​                                                                                                  |   ​ |
| LEGAL MATTERS                                                                                      | 132 |
| ​                                                                                                  |   ​ |
| WHERE YOU CAN FIND MORE INFORMATION                                                                | 132 |
| ​                                                                                                  |   ​ |
| INDEX TO FINANCIAL STATEMENTS                                                                      | F-1 |

No one has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. For investors outside the United States: We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.

1

FREQUENTLY USED TERMS Unless otherwise stated or unless the context otherwise requires, the terms “we,” “us,” “our,” the “Registrant,” the “Company” and “ParentCo” refer to Liminatus Pharma, Inc. (formerly known as Iris Parent Holding Corp.), a Delaware corporation, after giving effect to the Business Combination (as defined below), and where appropriate, our wholly-owned subsidiaries (including Liminatus Pharma, LLC) following the Closing Date (as defined below). Furthermore, unless otherwise stated or unless the context otherwise requires, references to “Iris” refer to Iris Acquisition Corp (formerly known as Tribe Capital Growth Corp I), a Delaware corporation, prior to the Closing Date, and references to “Liminatus” refer to Liminatus Pharma, LLC, a Delaware limited liability company, prior to the Closing Date. All references herein to the “Board” refer to the board of directors of the Company. In addition, in this prospectus:

| ● | “Business Combination” means the Transactions contemplated by the Business Combination Agreement and the related agreements. |

| ● | “Cantor” means Cantor Fitzgerald & Co. |

| ● | “CD47 Product” means any past and future product developed and to be developed using CD47 antibody drugs. |

| ● | “Class B Common Stock” means the Class B common stock, par value $0.0001 per share, of Iris. |

| ●